SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob zagorin who wrote (834)10/3/1997 1:12:00 AM
From: D.Right   of 2173
 
Dear Bob:

It is said in the article that they have enrolled 1,800 patients in the four on-going trials. I believe the target is 2,000 patients. In their annual report, they said the enrollment should be done in the 3rd quarter. I guess the results from Aug. made them double-check everything. Hopefully, the 200 more patients won't take too much longer. If 1,800 patients take them less than ten months (since the middle of last Dec.), then 200 more should be done in a month. Actually, I prefer them to take their time and do double-check everything.

Thanks for the post.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News